Project Grant R01AI089588

This federal Project Grant award of $294,583, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel cost-effective multispecific antibody therapeutic product for dengue by Mapp Biopharmaceutical, Inc. The goal is to create a therapeutic that combines the efficacy of two broadly neutralizing antibodies into a single half-life extended molecule, enabling higher...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $781,718 Project Grant through its Allergy and Infectious Diseases Research program (CFDA 93.855) to Loyola University of Chicago to develop a novel T cell-based vaccine to prevent Dengue and Zika virus infections. The 5-year project aims to create a vaccine that induces cytotoxic T cells targeting the Zika virus non-structural protein 3, without causing antibody-dependent enhancement observed with vaccines targeting the...

This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research grant program (CFDA 93.855), supports a Phase 2B clinical trial to assess the quality and balance of dengue immunity elicited by prime-boost combinations of the dengue vaccines TAK-003 and Butantan-DV. The $877,587 award to Emory University aims to study whether a heterologous prime-boost vaccination approach can generate a durable and...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $808,919 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Trustees of Boston University. The 5-year grant, which began on September 18, 2025, aims to develop novel aglain derivatives as host-targeted antivirals against dengue virus (DENV) and other mosquito-borne arboviruses. The research program seeks to optimize the aglain chemical series and study their modulation of the host...

This Project Grant award of $303,274 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports Antiger Therapeutics Inc., a startup biotech company, in developing targeted immunotherapies for Type 1 Diabetes (T1D). The primary objective is to engineer Peptide-HLA-DQ8 complex biologics that can selectively block the pathogenic T cells responsible for the autoimmune response in T1D. This innovative...

The Flavivirus and Alphavirus REVAMPP (FLARE) Center, funded by a $46,715,173 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), is developing and optimizing protein nanoparticle, virion-based, and mRNA vaccine platforms, as well as monoclonal antibody-based treatments to rapidly respond to emerging flaviviruses and alphaviruses with pandemic potential. The Center integrates the work of multiple...

This federal Project Grant award of $649,530.00, awarded on July 7, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of B cell receptor (BCR)-dependent infection as a mechanism of immune-mediated enhancement of Dengue virus (DENV) infection and pathogenesis. The funded research aims to explore how cross-reactive non-neutralizing antibodies, when expressed...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Qrono, Inc., a for-profit medical research and development company. The grant funding supports the development of QR402, a first-in-class, oral nanomedicine that uses an AMPK pathway agonist to target intestinal dendritic cells and restore immunological tolerance as a preventative therapy for type 1 diabetes. The goal is to...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $281,786 to L2 Diagnostics LLC for the development of a safe and effective viral vector-based vaccine to induce both humoral and cellular immune protection against Powassan virus. The goal is to leverage the Modified Vaccinia Ankara vector platform to stimulate robust antibody and T cell responses that...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $123,280 project grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to Instituto De Biologia Molecular Y Celular De Rosario (IBR) in Argentina. The grant aims to investigate the adaptive immune response against Trypanosoma cruzi, the parasite that causes Chagas disease, with the goal of developing effective vaccine candidates. The research will focus on enhancing CD8+ T cell...